Aptimmune Launches Industry’s First Inactivated Mucosal Influenza A Virus Vaccine in Swine (IAV-S)

with No Comments

CHAMPAIGN, Illinois (November 15, 2017) – Aptimmune Biologics introduces the industry’s first inactivated mucosal influenza A virus in swine (IAV-S) vaccine administered via nasal spray.  Aptimmune’s IAV-S vaccine utilizes the BARRICADE™ proprietary vaccine formulation that gives swine producers and veterinarians a completely different approach to conventional inactivated injectable and live virus vaccines for safely preventing and managing respiratory disease.

This inactivated mucosal vaccine is a new class of vaccines that mitigates respiratory disease at the point of entry. BARRICADE™ IAV-S combines three core components essential for effective disease protection: First, contemporary influenza type A antigen relevant for current application. Second, a powerful and safe immune-stimulating adjuvant. Lastly, Aptimmune’s proprietary nanoparticles deliver the vaccine payload to immune cells at the mucosal surface.

“BARRICADE™ IAV-S has shown to target immune cells at the respiratory surface, where the pig is naturally exposed to infection. This revolutionary approach provides veterinarians and producers the opportunity to produce an IAV-S vaccine which may contain up to five contemporary influenza type A strains, such as H1N1, H1N2 and H3N2.

“This inactivated-virus mucosal vaccine with its needleless, intranasal administration is safe to pigs, people, and is PQA-Plus friendly, making it an effective alternative to conventional IAV-S vaccines,” says Jessica Seate, DVM, professional services veterinarian for Aptimmune Biologics.

BARRICADE™ IAV-S is the second revolutionary, intranasally administered mucosal swine vaccine product introduced by Aptimmune this year, says Aaron Gilbertie, Aptimmune CEO. “Our BARRICADE™ PRRS vaccine continues to perform well on swine farms across the country, under some of the toughest disease conditions, and has validated our collaborative innovation model for developing and manufacturing custom mucosal vaccines. And because our PRRS and IAV-S vaccines utilize the same BARRICADE™ technology, they can be combined and administered together to prevent these two important diseases when appropriate.”

BARRICADE™ IAV-S vaccine is available in 250-mL and 500-mL bottles. The company recommends pigs be vaccinated intranasally once at 7-10 days of age and again at weaning (approximately 3-4 weeks of age). Aptimmune’s IAV-S vaccine formulated with BARRICADE™ technology includes a 21-day withdrawal period, the shortest allowed for custom vaccines.

For more information on the industry’s first inactivated mucosal IAV-S vaccine with BARRICADE™ technology, contact your swine veterinarian or visit aptimmune.com.

Aptimmune Biologics, based in Champaign, Ill., specializes in developing and marketing a portfolio of revolutionary mucosal vaccines that provide answers for the most costly viral diseases impacting the swine industry. Aptimmune’s first vaccines are focused on addressing two major viral respiratory pathogens, Porcine Reproductive and Respiratory Virus (PRRSV) and Influenza A virus in swine (IAV-S). To learn more visit aptimmune.com.




Aaron Gilbertie
60 Hazelwood Dr
Champaign, IL 61820